(RTTNews) - AbbVie (ABBV) Wednesday reported updated results from the Phase 2 EPCORE NHL-6 study evaluating the feasibility of outpatient monitoring of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
In the study, 88 patients received the first full dose of epcoritamab monotherapy. Of these, 81 patients (92%) were monitored in the outpatient setting and seven (8%) in the inpatient setting. Results from the study showed that the incidence and severity of cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) following treatment with epcoritamab were consistent with previous epcoritamab studies in R/R DLBCL.
The study also showed an overall response rate (ORR) of 64.3% and a complete response (CR) rate of 47.6%, at a median follow-up of 5.8 months, in patients treated with epcoritamab after only one prior line of systemic therapy.
These results were shared today at the 13th Society of Hematologic Oncology (SOHO) Annual Meeting.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
